c-RET
Os inibidores de c-RET têm como alvo o proto-oncogene RET (Rearranged during Transfection), que codifica uma tirosina quinase receptora envolvida no crescimento, diferenciação e sobrevivência celular. A ativação anormal da sinalização RET pode levar à proliferação celular descontrolada e à resistência à apoptose, contribuindo para o desenvolvimento de cânceres como o carcinoma medular da tireoide e o câncer de pulmão de células não pequenas. A inibição de c-RET pode induzir apoptose em células cancerígenas e é uma abordagem promissora na terapia oncológica direcionada. Na CymitQuimica, oferecemos uma variedade de inibidores de c-RET de alta qualidade para apoiar sua pesquisa em oncologia, transdução de sinais e apoptose.
Foram encontrados 51 produtos de "c-RET"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
BT-13
CAS:<p>BT-13 activates RET receptor without GFLs, fostering sensory neuron neurite growth in vitro.</p>Fórmula:C23H27F4N3O4SPureza:99.23%Cor e Forma:SolidPeso molecular:517.54RET-IN-4
CAS:<p>RET-IN-4: Oral RET inhibitor, IC50 ~1 nM for variants. Selective over JAK2/FLT3. Potent anticancer use.</p>Fórmula:C27H31FN10O2Cor e Forma:SolidPeso molecular:546.611RET-IN-26
<p>RET-IN-26 (compound D5) is a kinase inhibitor that selectively targets the RET protein with an IC50 value of 0.33 μM [1].</p>Cor e Forma:Odour SolidZeteletinib hemiadipate
CAS:<p>Zeteletinib hemiadipate (BOS-172738; DS-5010) is an oral RET kinase blocker with nanomolar potency and strong anti-tumor properties.</p>Fórmula:C56H56F6N8O12Cor e Forma:SolidPeso molecular:1147.098YW-N-7 TFA
<p>YW-N-7 (TFA) is a PROTAC designed to target, inhibit, and degrade RET kinase, demonstrating a DC50 of 88 nM. It exhibits antitumor activity in xenograft mouse models driven by KIF5B-RET, making it a valuable compound for cancer research.</p>Fórmula:C58H63F3N12O9Cor e Forma:SolidPeso molecular:1129.19RET ligand-1
CAS:<p>RETligand-1 is a target protein ligand that specifically interacts with RET and can be utilized in the synthesis of the PROTAC LDD39.</p>Fórmula:C28H24F2N6O3Cor e Forma:SolidPeso molecular:530.525QZ2135
<p>QZ2135 (compound 20) is a PROTAC degrader that specifically targets RET and exhibits antitumor activity in vivo within a Ba/F3-KIF5B-RET-G810C xenograft mouse model. The compound demonstrates degradation activity with DC50 values of 4.7 nM (WT), 17.2 nM (V804M), and 73.8 nM (G810C) when targeting KIF5B-RET. QZ2135 is composed of the target protein ligand (red part) RETligand-3, the E3 ligase ligand (blue part) Lenalidomide-F, and the PROTAC Linker (black part) 7-Iodohept-1-yne, wherein the target protein ligand combined with the linker forms the conjugate RETLigand-Linker Conjugate-1.</p>Fórmula:C53H54N12O4Cor e Forma:SolidPeso molecular:923.07AD57 (hydrochloride)
CAS:<p>AD57, a polypharmacological agent, blocks RET kinase (IC50: 2 nM), disrupts related kinases, and hinders cancerous activities like invasion and proliferation.</p>Fórmula:C22H21ClF3N7OPureza:98%Cor e Forma:SolidPeso molecular:491.9RET Ligand-Linker Conjugate-1
<p>RET Ligand-Linker Conjugate-1 consists of a complex formed by a RET ligand and a linker, which can be utilized in the synthesis of QZ2135.</p>Fórmula:C40H44N10OCor e Forma:SolidPeso molecular:680.84PLM-101
<p>PLM-101 is an anticancer compound orally active against acute myeloid leukemia by targeting FLT3 and RET.</p>Fórmula:C22H22FN5O2Cor e Forma:SolidPeso molecular:407.44Compound TPX-0046
CAS:<p>Compound TPX-0046 is an inhibitor of RET. Compound TPX-0046 can inhibit the RET autophosphorylation. Compound TPX-0046 can be used for the research of cancer.</p>Fórmula:C21H21FN6O3Pureza:99.94%Cor e Forma:SoildPeso molecular:424.43RET ligand-3
<p>RETligand-3 is the ligand for PROTAC QZ2135, which targets RET.</p>Fórmula:C38H42N10O3Cor e Forma:SolidPeso molecular:686.81RET-IN-28
CAS:<p>RET-IN-28 (Compound 16) is an inhibitor of RET (a transmembrane receptor tyrosine kinase). It specifically inhibits the activity of a mutant RET enzyme (RET-V804M) and is utilized in cancer research.</p>Fórmula:C26H29N9Cor e Forma:SolidPeso molecular:467.57BT44
CAS:<p>BT44, a potent second-gen GDNF mimetic, is a lead for treating neurodegeneration.</p>Fórmula:C28H27F4N3O4SPureza:99.87%Cor e Forma:SoildPeso molecular:577.59trans-Pralsetinib
CAS:<p>trans-Pralsetinib (trans-BLU-667) is an inhibitor of rearranged during transfection (RET).</p>Fórmula:C27H32FN9O2Pureza:98%Cor e Forma:SolidPeso molecular:533.6Pralsetinib
CAS:<p>Pralsetinib (Blu667) (BLU-667) is a highly potent, selective RET inhibitor (IC50s: 0.4, 0.3, 0.4, 0.4, and 0.4 nM for WT RET, RET mutants V804L, V804M, M918T</p>Fórmula:C27H32FN9O2Pureza:97.88% - 99.8%Cor e Forma:SolidPeso molecular:533.6WHI-P180
CAS:<p>WHI-P180 (Janex 3) is a potent EGFR and Cdk2 inhibitors with IC50 of 4.0 and 1.0 uM, respectively.</p>Fórmula:C16H15N3O3Pureza:99.21%Cor e Forma:SolidPeso molecular:297.31SPP-86
CAS:<p>SPP-86 is an effective and selective cell-permeable inhibitor of RET tyrosine kinase with an IC50 of 8 nM.</p>Fórmula:C16H15N5Pureza:99.53%Cor e Forma:SolidPeso molecular:277.32Pyrazoloadenine
CAS:<p>Pyrazoloadenine (4-Aminopyrazolo[3,4-d]pyrimidine) is the inhibitor of human xanthine oxidase.</p>Fórmula:C5H5N5Pureza:99.02%Cor e Forma:Beige PowderPeso molecular:135.13WHI-P180 hydrochloride
CAS:<p>WHI-P180 (Janex 3) inhibits RET, KDR and EGFR with IC50 values of 5 nM, 66 nM and 4 μM, respectively. WHI-P180 is a multi-kinase inhibitor.</p>Fórmula:C16H16ClN3O3Cor e Forma:SolidPeso molecular:333.77
